Prior Antithrombotic Use is Associated with Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke
| Contribuinte(s) |
University of Aberdeen, Medicine, Medical Sciences & Nutrition, Other Applied Health Sciences |
|---|---|
| Data(s) |
05/08/2016
05/08/2016
19/07/2016
|
| Resumo |
Sources of Funding The GWTG-Stroke program is currently supported in part by a charitable contribution from Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership and the American Heart Association Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past through support from Boehringer-Ingelheim and Merck. These funding agencies did not participate in design or analysis, manuscript preparation, or approval of this study. Peer reviewed Postprint |
| Identificador |
Myint , P K , Hellkamp , A S , Fonarow , G C , Reeves , M J , Schwamm , L H , Schulte , P J , Xian , Y , Suter , R E , Bhatt , D L , Saver , J L , Peterson , E D & Smith , E E 2016 , ' Prior Antithrombotic Use is Associated with Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke ' Stroke . , 10.1161/STROKEAHA.115.012414 0039-2499 PURE: 67611368 PURE UUID: 6b04697b-969a-4692-a087-51641884c934 |
| Idioma(s) |
eng |
| Relação |
Stroke |
| Palavras-Chave | #ischemic stroke #prognosis #functional outcome #mortality #antiplatelet #anticoagulant #antithrombotic #antiplatelet agents #antithrombotic agents #stroke #R Medicine #R |
| Tipo |
Journal article |
